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Abstract 
 
Purpose: To compare the outcomes of pediatric and adolescent extracranial malignant 
germ cell tumor (GCT) patients treated with either carboplatin and cisplatin on clinical 
trials conducted by &KLOGUHQ¶V Oncology Group (COG) and the &KLOGUHQ¶V Cancer and 
Leukemia Group (CCLG). 
 
Methods: The Malignant Germ Cell International Consortium (MaGIC) has created a 
database of the GCT clinical trials conducted since 1983 by COG (United States, Canada, 
Australia), which used cisplatin-based regimens, and by CCLG (United Kingdom), which 
used carboplatin-based regimens. Using the parametric cure model, this study compared 
the overall 4-year event-free survival (EFS), stratified by age, stage, site, and the a-priori 
defined MaGIC µrisk¶ groups: standard risk ((SR) 1 (EFS>80%; age<11years) , SR2 
(EFS>80%, age>11y), and poor risk (EFS<70%, age>11y).  
 
Results:  Cisplatin-based therapy was used in 620 patients; carboplatin was used in 163 
patients. In the overall multivariate cure model, the two regimens did not differ 
significantly (cisplatin: 4y-EFS 86%; 95% confidence interval (CI) 83-89% vs. 
carboplatin 4y-EFS 86%; 95% CI 79-90%; p=0.87). No significant differences were 
noted in stratified analyses by site, stage, age and MaGIC risk group: SR1 (p=0.20), SR2 
(p=0.55) or PR (p=0.72) patients. 
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Conclusions: In these trials conducted contemporaneously, there is no significant 
difference in outcome observed overall, or any subset of patients, who were treated with 
regimens containing cisplatin  vs. carboplatin These results suggested sufficient equipoise 
to justify a randomized trial to evaluate the effectiveness of carboplatin vs. cisplatin in the 
treatment of children, adolescents and young adults with standard risk GCT, which is 
currently underway. 
 
Word count: 250  
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Introduction 
After the landmark study by Einhorn et al. 1  in 1977, cisplatin-based therapy was rapidly 
accepted as standard of care for testicular cancer, and testicular cancer became ³WKH
PRGHORIDFXUDEOHQHRSODVP´2.  However, cure comes with the price of significant 
immediate and often permanent toxicities, including hearing loss, tinnitus, peripheral 
neuropathy, and nephrotoxicity.3 With longer follow-up, cisplatin has been associated 
with reduced fertility, at least in males, 4 and testicular cancer survivors have a two-fold 
increase in risk of second malignant solid neoplasms (in addition to the established risk of 
etoposide-induced leukemias) and early onset of cardiovascular disease.5,6  
 
Other platinum-based compounds were developed, with hopes that a less toxic alternative 
to cisplatin could be found. Carboplatin appeared to be a promising alternative, causing 
less oto- and nephrotoxicity.  Four randomized clinical trials (RCTs) of carboplatin vs. 
cisplatin were conducted in the late 1980s in adult men with good-risk non-seminomatous 
testicular germ cell tumors.7-10 Unfortunately, carboplatin was inferior to cisplatin in 
every trial. However, carboplatin was being investigated in adult men with testicular 
cancer, carboplatin was also adopted for treatment of germ cell tumors (GCTs) in 
children and adolescents by several pediatric clinical trial groups. As summarized by 
Shaikh et al,11 in the three pediatric studies using carboplatin at a higher dose and 
frequency than used in adult trials of carboplatin in men with testicular cancer, 158/179 
(88%) of children remained event-free. Since none of the pediatric trials using 
carboplatin were randomized, the relative effectiveness of carboplatin vs. cisplatin for 
children and adolescents with GCT remains unclear. 
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In 2010, investigators from &KLOGUHQ¶V2QFRORJ\*URXS (COG) (United States, Canada 
and Australia) and &KLOGUHQ¶V&DQFHUDQG/HXNHPLD*URXS (CCLG) (United Kingdom) 
created the Malignant Germ Cell International Consortium and agreed to pool 25 years of 
clinical trial data on pediatric and adolescent GCTs. Analysis of MaGIC data identified 
three factors predicting worse outcome: age 11 years or more, advanced stage of disease 
and either an ovarian or an extragonadal primary.12 MaGIC proposed a new risk 
stratification re-classifying pediatric and adolescent GCT into standard (EFS >80%) and 
poor (EFS <70%) risk groups based on these clinical features.12 In this study, we 
compare outcomes of treatment with carboplatin vs. cisplatin, overall and by site, stage, 
age as well as in the previously defined by MaGIC risk groups.  
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Methods 
Patients 
Details of MaGIC have been reported elsewhere.12 Briefly, patients with extracranial 
malignant GCTs treated on clinical trials conducted by either CCLG or COG between 
1983 and 2008 were included in the MaGIC dataset, including CCLG GC1 and GC8901 
(GC2) from the UK and INT0097, INT0106, P9747, AGCT01P1, and AGCT0132 from 
COG (Supplemental Table 1).  
 
In the CCLG clinical trials, the regimen µ-(%¶ consisted of carboplatin 600 mg/m2 (AUC 
7.9), etoposide 360 mg/m2 and bleomycin 15 mg/m2 given every 21 days for n+2 cycles 
(where n is the number of cycles needed to achieve marker normalization; median =5). In  
COG, the regimen µPEb (or pediatric-BEP) consisted of cisplatin 100 mg/m2, etoposide 
500 mg/m2 and bleomycin 15mg/m2 every 21 days. The number of days over which the 
total dose of PEb was delivered and the number of cycles (3-6) varied between protocols. 
One COG trial added another agent (cyclophosphamide - AGCT01P1); another COG trial 
tested high-dose cisplatin (200 mg/m2 per cycle - INT0097). Further details of the 
therapies delivered on each trial are summarized in Supplemental Table 1.   
 
Inclusion in this analysis required a patient had been treated with a platin-based regimen, 
and the primary tumor contained malignant non-germinomatous GCT histology (i.e. yolk 
sac tumor, choriocarcinoma, or embryonal carcinoma). There were a total of 1300 
patients in the seven studies. The upper age limit varied from age 15y on CCLG trials to 
21y on most trials in COG (see Supplemental Table 1). Stage I patients who were initially 
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treated with surgery and active surveillance, but who were subsequently treated with 
chemotherapy because of recurrent disease, were excluded from this analysis (n=69), 
because of very high rate of salvage in this group, on both regimens.13,14,15 Stage I 
patients who received chemotherapy immediately following surgery however, as was 
standard practice for certain sites (extragonadal and ovarian), were included. Patients 
treated with surgery only (n=363) or non-platin-based chemotherapy (n=4), those with 
either pure immature teratoma (n=11) or pure seminoma/dysgerminoma (n=68), and 
those with missing data on stage (n=2) were excluded from the analysis. After exclusions, 
the dataset included 783 patients. 
 
Statistical analysis 
Outcome Measure: Event-free survival (EFS): Patient outcome was calculated as time 
from the start of chemotherapy until disease progression, diagnosis of a second malignant 
neoplasm (SMN) death, or date of last follow-up, whichever came first. A patient who 
experienced disease progression, SMN or death was an event for analysis; otherwise, the 
patient was censored at last contact. 
 
Statistical Model: A non-mixture cure model was used to model the relationship between 
treatment and EFS. 13 This model has been shown to provide excellent fit to childhood 
cancer outcome data. The model provides a coherent methodology to investigate effects 
of treatment on rate of failure separately from their effect on ultimate cure. A model with 
a Weibull kernel with no covariates and cured fraction modeled as a logistic function of 
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the patient characteristics was used.  This was the same model used in previous MaGIC 
analyses18. 
 
The Kaplan-Meier estimate of proportion event-free as a function of time since the start 
of follow-up was calculated for selected groups of patients. The log rank test was used to 
compare equality of risk across selected patient groups.16 The parametric and non-
parametric estimators of EFS as a function of time were compared as suggested by 
Sposto et al.17 The hazard ratio (HR) of patients treated with JEB relative to PEb was 
estimated by Cox regression. For comparisons where maximum likelihood estimate of 
HR did not converge, the method of Firth18 was applied to obtain a finite estimate of HR 
and its 95% confidence interval.  A two-sided p-value of 0.05 or less s identified as 
significant. 
 
Covariates:  
 
MaGIC-defined risk groups: The significant prognostic factors (agey, advanced stage 
and either ovarian or extragonadal site) identified in the previous MaGIC risk 
stratification were used to construct two risk groups: standard risk (SR) (EFS>80%) and 
poor risk (PR) (EFS<70%).12 The standard risk group is divided by age into two further 
categories. Patients age 10y or less are in the SR1 group, which includes COG stage II-IV 
and all sites (ovarian, extragonadal, and testicular). Patients age 11y and older with COG 
stage II-III ovarian, stage II extragonadal and IGCCC good risk testicular are in the SR2 
group. The poor risk group is comprised of patients age 11y and older with COG stage IV 
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ovarian, COG stage III-IV extragonadal, and IGCCC intermediate and poor risk 
testicular. The outcomes of patients treated on JEB vs. PEb were compared in these three 
summary MaGIC risk groups. 
 
Other covariates: Age was dichotomized as 0 ± 10y or greater than or equal to 11y. The 
serum AFP in ng/ml was defined as the measurement closest to, but not later than, the 
first surgical intervention prior to the start of chemotherapy.17 In prior analyses, multiple 
methods of defining the optimal cutpoints for AFP were examined, but none were more 
informative than the traditional cutpoint of > vs. QJPOStage was defined used 
COG criteria.12 Histology was defined either as pure yolk sac tumor, choriocarcinoma, 
embryonal carcinoma, or mixed malignant GCT (containing one of these components 
with teratoma, or at least two of these components without teratoma). Site was defined as 
testicular, ovarian, or extragonadal GCT. In sensitivity analyses, we included only 
patients on COG trials using standard dose cisplatin and excluded any patient who had 
also received either cyclophosphamide or high dose cisplatin. 
 
Results 
A comparison of  patient characteristics treated on PEb vs. JEB is presented in Table 1. 
On average, patients on a carboplatin-containing regimen received one more cycle of 
chemotherapy than those of a cisplatin-containing regimen (5 vs. 4 cycles). Of note, other 
patient characteristics are not balanced between the two regimens because these data 
represent clinical trial data from two different clinical trial organizations and are not a 
randomized trial. Patients treated with carboplatin were more likely to be younger (61% 
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were ages 0-4y vs. 49% in the cisplatin group), have extragonadal disease (57% vs. 40%), 
pure yolk sac tumor (64% vs. 47%), pre-operative AFP>10,000 ng/ml (60% vs. 38 %) 
and stage IV disease (34% vs.24 %).  
 
In Table 2, the 4-year estimates of EFS and 95% confidence intervals (95% CI) are 
presented overall and by the univariate risk factors19. When the entire analytic population 
is considered, there is no significant difference in outcome between PEb (4y EFS 86%) 
vs. JEB (4y EFS 86%; HR 1.04; p=0.87). Risk of an event also was not significantly 
different in stratified univariate analyses defined by age, primary tumor site, histology, 
pre-operative AFP level, or stage.  
 
In Figure 1, EFS is presented as a forest plot of hazard ratios in combinations of age, site 
and stage, as previously defined by MaGIC. (A table of EFS in these combined risk 
groups is included as Supplemental Table 2). The outcome comparing PEb vs. JEB did 
not exclude zero in any combination of age, stage or site. In some strata, the number of 
patients treated, particularly on the JEB regimen, was relatively small and consequently 
the confidence intervals are quite wide. Patients were also classified by the new MaGIC 
risk groups: SR1, SR2, and PR. Outcomes between JEB and PEb were again not 
significantly different in either SR1 [(HR) 1.50; p=0.20), SR2 (HR 1.34; p=0.55) or PR 
(HR 0.80; p=0.72)] (Supplemental Table 2). 
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In Figure 2, overall EFS survival curves are presented overall, for age, stage, site and by 
MaGIC risk group (SR1, SR2 and PR). EFS is not significantly different in any of these 
groups.  
 
We performed multivariate modeling of outcome using the cure model17. After including 
in the model the variables for age, site and stage, effect of treatment (PEb vs JEB) was 
not significant (estimated log odds -0.09; p=0.73) (Table 3). In sensitivity analysis, we 
included only patients treated with standard PEb (excluding patients treated with PEb + 
cyclophosphamide on AGCT01P1 and patients treated with high dose cisplatin on 
INT0097) and none of the conclusions were significantly altered (Supplemental Table 3). 
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Discussion 
No significant difference in outcome was observed among pediatric and adolescent 
extracranial GCT patients treated with a cisplatin-based regimen (PEb) vs. a carboplatin-
based regimen (JEB), when comparing groups by age, site and stage. Additionally, the 
treatment regimen received (cisplatin vs. carboplatin) was not significant in the results of 
the multivariate model (Table 3) controlling for other known risk factors. We 
acknowledge that individual risk stratum is relatively small in terms of total patient 
numbers, nonetheless, in the absence of randomized data in this age group, we suggest 
there is equipoise regarding relative effectiveness of cisplatin vs. carboplatin for pediatric 
and adolescent GCT. 
 
Our conclusions differ from those observed in the four published randomized 
comparisons of cisplatin vs. carboplatin in adult men with non-seminomatous testicular 
germ cell tumors, which are summarized in Supplemental Table 4.7-10 There are several 
explanations for the observed differences. Our results are not derived from a randomized 
trial but rather comprise an analysis of clinical trials conducted contemporaneously and 
thus are admittedly less conclusive. However, there are several aspects of the design of 
adult trials predisposing the results to be unfavorable to carboplatin. Most importantly, all 
of the adult trials used a dose of carboplatin significantly lower than the dose used in 
pediatric regimens (AUC 3-5 vs. AUC 7.9 or 350-500 mg/m2  vs.600 mg/m2). The dose 
employed in the adult trials may therefore have been insufficient. Secondly, 2 7,10 of the 4 
trials administered carboplatin every 28 days whereas the cisplatin regimen was 
administered every 21 days. Inadequate dose-density of carboplatin arms may have 
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predisposed the carboplatin arm to do worse. A third trial 8 used a lower dose of etoposide 
on the carboplatin arm of the trial than on the cisplatin arm of the trial (360mg/m2 vs 
500mg/m2). This lower dose of etoposide has been shown to produce inferior results by 
Grimison et al. 20 Although these adjustments (increased cycle length and decreased 
etoposide dose) were made to compensate for the expected increased myelotoxicity of 
carboplatin, both would be expected to bias the results against carboplatin. 
 
Another explanation for the apparent enhanced performance of carboplatin in pediatric 
GCTs is that underlying biology of pediatric disease is different from adult GCTs.  In 
younger children, histology is likely to be predominately yolk sac tumor whereas in 
adolescents and adults, histology is generally ³mixed´.  GCTs in younger patients show 
variable loss of imprinting (LOI) whereas GCTs of adolescents and adults, have more 
complete LOI, implying the origin of the tumor occurred at a later stage in embryologic 
development..21 Using comparative genomic hybridization, GCTs arising in younger 
patients consistently show a loss of 1p and 6q, whereas post-pubertal children exhibit 
pathognomonic amplification of 12p seen in adults.22 Gene expression profiling 
segregates pediatric vs. adult GCTs.22 The biology of pediatric GCTs may render these 
tumors more inherently sensitive to chemotherapy.23  
 
The study has its limitations. Although the data presented here are not derived from a 
randomized comparison, the data have been harmonized to provide the maximal 
comparability possible outside of an RCT.  The precision is greater among younger 
patients (age 10y and less) due to larger sample size (n=507). The sample size in patients 
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aged 11y or older is smaller, however analysis of 276 adolescents age 11y and older (233 
treated with cisplatin, and 43 treated with carboplatin), there is no evidence that 
carboplatin is inferior (p=0.96). However, upper age limit on the UK carboplatin trials 
was age 15y, and therefore we cannot comment on the relative effectiveness in older 
adolescents. Another caveat to our results is that we do not know the actual numbers on 
cycles delivered on each regimen because this information was not collected as part of 
VHYHUDORIWKHFOLQLFDOWULDOVRQO\WKHQXPEHURIF\FOHV³SUHVFULEHG´E\WKHUHJLPHQ,Q
general, however, patients who received carboplatin were prescribed on average one 
more cycle of chemotherapy than those who received cisplatin (5 vs. 4 cycles). Therefore, 
it is possible that an additional cycle of carboplatin is needed to achieve similar outcomes 
to those of cisplatin.   
 
Based on available data, a randomized controlled trial of carboplatin vs. cisplatin, using 
pediatric carboplatin dosing and schedule, was deemed warranted and is underway (COG 
AGCT1531). To have sufficient sample size, particularly among children age 10y or less 
in whom incidence of GCT is lower, enrollment from international sites is necessary. 
AGCT1531 will enroll patients from Canada, United States, Australia, New Zealand, 
United Kingdom, TATA Memorial Hospital in Mumbai, and Japanese &KLOGUHQ¶V&DQFHU 
Group to meet accrual goals. This trial will clarify relative effectiveness of carboplatin vs. 
cisplatin in standard risk patients age 0-25y and will carefully document any associated 
toxicities. The intention is to facilitate patient-centered conversations in the future that 
can enumerate trade-offs in terms of efficacy vs. toxicity of cisplatin vs. carboplatin.  
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Figure 1: Forrest plot showing estimates of hazard ratio (HR) of patients treated with Jeb vs PEb, according to prognostic risk groups. 
Overall  (I-squared = 0.0%, p = 0.999)
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Figure 2. Kaplan-Meier estimates of EFS of patients treated with PEb vs. JEb. Overall (2a), by 
age (2b), by stage (2c), by site (2d), by MaGIC risk group (2e) 
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Table 1: Patient characteristics treated with Cisplatin-based regimens (PEb) vs. Carboplatin-based 
regimens (JEB) in MaGIC.  
 Assigned Treatment  
 PEb (n; %) JEB (n, %) Total (%) 
Total 620 (79.2%)  163 (20.8%) 783 
Median Cycles (Range) 4 (3-7) 5 (1-9)  
Age (years)    
0 ± 10 387 (62.4%) 120 (73.6%) 507 (64.7%) 
11+ 233 (37.6%) 43 (26.4%) 276 (35.3%) 
Site    
Testes 147 (23.7%) 16 (9.8%) 163 (20.8%) 
Ovarian 224 (36.1%) 54 (33.1%) 278 (35.5%) 
Extragonadal 
    Sacrococcygeal 
    Mediastinal 
    Other EG 
  249 (40.2%) 
  124 (20.0%) 
    56 (9.0%) 
    69 (11.1%) 
    93 (57.1%) 
    45 (27.6%) 
    13 (8.0%) 
    35 (21.5%) 
342 (43.7%) 
169 (21.6%) 
  69 (8.8%) 
104 (13.3%) 
Histology    
Embryonal Carcinoma 5 (0.8%) 3 (1.8%) 8 (1.0%) 
Yolk Sac 292 (47.1%) 104 (63.8%) 396 (50.6%) 
Choriocarcinoma 9 (1.4%) 1 (0.6%) 10 (1.3%) 
Mixed GCT 280 (45.2%) 55 (33.8%) 335 (42.8%) 
Other/Missing 34 (5.5%) 0 34 (4.3%) 
AFP    
0 ± 9,999 358 (57.7%) 61 (37.4%) 419 (53.5%) 
>= 10,000 233 (37.6%) 98 (60.1%) 331 (42.3%) 
Missing 29 (4.7%) 4 (2.5%) 33 (4.2%) 
Stage    
I 125 (20.1%) 28 (17.2%) 153 (19.5%) 
II 129 (20.8%) 35 (21.5%) 164 (21.0%) 
III 218 (35.2%) 44 (27.0%) 262 (33.5%) 
IV 148 (23.9%) 56 (34.3%) 204 (26.0%) 
Treatment Regimena    
HD-PEb* 156 (25.2%) 0 156 (19.9%) 
PEb 450 (72.6%) 0 450 (57.5%) 
C-PEb** 14 (2.2%) 0 14 (1.8%) 
JEb 0 163 (100%) 163 (20.8%) 
             *HD-PEb: PEb with high dose cisplatin (200 mg/m2) 
             ** C-PEb: PEb plus cyclophosphamide 
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Table 2: Comparison of 4-year KM EFS (95% Confidence Intervals) in Patients Treated with 
cisplatin (PEb) vs. carboplatin (JEB).  
 
Assigned Treatment 
  
 
PEb (4-year KM 
EFS; 95% CI) 
JEb (4-year KM 
EFS; 95% CI) p-Value 
HR*       (95% CI) 
Overall 0.86 (0.83-0.89) N=620 
0.86 (0.79-0.90) 
N=163 0.87 
1.04     (0.65-1.65) 
Age (years)     
<11 0.89 (0.86-0.92) N=387 
0.87 (0.80-0.92) 
N=120 0.54 
1.20     (0.66-2.18) 
>= 11 years 0.81 (0.75-0.86) N=233 
0.81 (0.66-0.90) 
N=43 0.96 
0.98     (0.46-2.09) 
Site  
   
Testes 0.85 (0.78-0.90) N=147 
1 
N=16 0.10 
0.185** 
(0.001-1.332) 
Ovarian 0.90 (0.85-0.93) N=224 
0.85 (0.73-0.92) 
N=54 0.38 
1.43     (0.64-3.22) 
Extragonadal 
 
Sacrococcygeal 
 
Mediastinal 
 
Other EG 
 
0.84 (0.79-0.88) 
N=249 
0.88 (0.81-0.92) 
N=124 
0.77 (0.63-0.86) 
N=56 
0.83 (0.72-0.90) 
N=69 
0.84 (0.74-0.90) 
N=93 
0.86 (0.72-0.94) 
N=45 
0.77 (0.44-0.92) 
N=13 
0.83 (0.66-0.92) 
N=35 
0.85 
 
0.80 
 
0.93 
 
0.87 
 
1.06     (0.58-1.93) 
1.13     (0.44-2.91) 
1.06     (0.30-3.76) 
1.08     (0.40-2.93) 
Histology     
Yolk Sac 0.88 (0.84-0.91) N=292 
0.87 (0.79-0.92) 
N=104 0.85 
1.06     (0.56-2.01) 
Mixed GCT 0.85 (0.81-0.89) N=280 
0.84 (0.71-0.91) 
N=55 0.80 
1.10     (0.53-2.27) 
AFP     
0 ± 9,999 0.89 (0.85-0.92) N=358 
0.93 (0.83-0.97) 
N=61 0.25 
0.55     (0.20-1.54) 
>= 10,000 0.84 (0.78-0.88) N=233 
0.80 (0.71-0.87) 
N=98 0.37 
1.29     (0.74-2.24) 
Stage     
I 0.90 (0.83-0.94) N=125 
1 
N=28 0.09 
0.17** (0.001-1.268) 
II 0.92 (0.85-0.96) N=129 
0.94 (0.79-0.99)  
N=35 0.66 
0.71     (0.16-3.26) 
III 0.87 (0.81-0.91) N=218 
0.82 (0.67-0.90) 
N=44 0.34 
1.46     (0.66-3.21) 
IV 0.78 (0.71-0.84) N=148 
0.76 (0.63-0.86) 
N=56 0.86 
1.06     (0.56-2.01) 
*PEb is the reference group 
** Estimated using the method of Firth 
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Supplemental Table 1: Pediatric Germ Cell Tumor Clinical Trials included in MaGIC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
National 
Group 
 
Eligibility of the Trial Treatment Regimen 
Cycle 
(days) 
Number of 
cycles 
Number 
of 
patients 
GC124 
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UK All patients with 
MGCT 
Etoposide 
120mg/m2 D1-3, 
Bleomycin 15 
IU/m2 D2,  
Cisplatin 100mg/m2 
D1 
21  n* + 2 
(n=courses to 
marker 
normalization) 
21  
GC225 UK All patients with MGCT 
JEB 21  n* + 2 163  
INT-106/ 
POG9048/CCG-
889114 
US Stage II testicular; 
Stage I-II ovarian 
PEB 21  4 (+2 if PR) 118  
INT-0097/ 
POG9049/CCG-
888226 
US Stage III and IV 
gonadal and 
extragonadal tumors 
PEB vs. HDPEB 21  4 (+2 if PR) 261  
P974927 
US Stage III and IV 
extragonadal tumors 
Amifostine 
825mg/m2 D1-5 + 
HDPEB 
21  4 (+2 if PR) 26 
AGCT01P128 
US Stage III and IV 
extragonadal tumors 
C-BEP 21  4 (+2 if PR) 14 
AGCT013229 US Stage I-III ovarian 
Stage I-IV testicular 
Stage I-II extragonadal 
Compressed PEB 21  3 (+3 if PR) 180  
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Supplemental Table 2: Comparison of 4-year KM EFS (95% Confidence Intervals) of Pediatric 
GCT Patients Treated with cisplatin (PEb) vs. carboplatin (JEB). 
  Assigned Treatment   
Tumor 
Site Stage and Age 
PEb (4-year 
KM EFS; 95% 
CI) 
JEb (4-year KM 
EFS; 95% CI) p-Value 
HR*        (95% 
CI) 
Ovarian Stage I-III, Age 
< 11 
0.95 (0.86-0.98)  
N=78 
1 
N=18 0.32 
0.45 (0.003-
4.25)**  
Ovarian Stage IV, Age < 
11 
0.80 (0.20-0.97) 
N=5 
0.67 (0.05-0.95) 
N=3 0.78 
1.49     (0.09-
23.94) 
Ovarian Stage I-III, Age 
>= 11 
0.87 (0.80-0.92) 
N=138 
0.81 (0.61-0.92) 
N=27 0.41 
1.52     (0.56-
4.14) 
Ovarian Stage IV, Age 
>= 11 
1 
N=3 
0.67 (0.19-0.90) 
N=6 0.90 
1.17     (0.11-
12.98) 
Testicular Stage I-III, Age 
< 11 
0.87 (0.77-0.93) 
N=78 
1 
N=5 0.40 
0.68 (0.005-
5.31)**--- 
Testicular Stage IV, Age < 
11 
0.93 (0.59-0.99) 
N=14 
1 
N=4 0.59 
1.22 (0.008-
21.88)**--- 
Testicular Stage I-III, Age 
>= 11 
0.91 (0.68-0.97) 
N=23 
1 
N=6 0.45 
0.71 (0.005-
8.78)**--- 
Testicular Stage IV, Age 
>= 11 
0.72 (0.53-0.84) 
N=32 
1 
N=1 0.57 
1.46 (0.01-
11.51)**--- 
EG Stage I-III, Age 
< 11 
0.92 (0.85-0.96) 
N=129 
0.92 (0.80-0.97) 
N=49 0.95 
1.04     (0.32-
3.30) 
EG Stage IV, Age < 
11 
0.83 (0.73-0.90) 
N=83 
0.75 (0.59-0.86) 
N=41 0.29 
1.55     (0.69-
3.48) 
EG Stage I-III, Age 
>= 11 
0.72 (0.49-0.86) 
N=26 
0.50 (0.01-0.91) 
N=2 0.46 
2.17     (0.26-
17.75) 
EG Stage IV, Age 
>= 11 
0.30 (0.06-0.60) 
N=11 
1 
N=1 0.45 
0.80 (0.006-
7.06)**--- 
Overall Stage I-III, Age 
< 11 
0.91 (0.87-0.94)  
N=285 
0.94 (0.86-0.98) 
N=72 0.40 
0.64     (0.22-
1.83) 
Overall Stage IV, Age < 
11 
0.84 (0.76-0.90) 
N=102 
0.77 (0.62-0.86) 
N=48 0.28 
1.52     (0.71-
3.28) 
Overall Stage I-III, Age 
>= 11 
0.85 (0.79-0.90) 
N=187 
0.83 (0.66-0.92) 
N=35 0.68 
1.21     (0.50-
2.94) 
Overall Stage IV, Age 
>= 11 
0.65 (0.49-0.77) 
N=46 
0.75 (0.31-0.93) 
N=8 0.61 
0.68     (0.16-
2.97) 
MaGIC 
Risk 
Group 
Standard Risk 1 0.90 (0.85-0.93) N=303 
0.85 (0.76-0.91) 
N=100 0.20 
1.50     (0.81-
2.77) 
Standard Risk 2 0.85 (0.77-0.90) N=143 
0.80 (0.58-0.91) 
N=25 0.55 
1.34     (0.50-
3.58) 
Poor Risk 0.62 (0.46-0.74) N=49 
0.70 (0.33-0.89) 
N=10 0.72 
0.80     (0.24-
2.71) 
*PEb is the reference group 
** Estimated using the method of Firth  
26 
 
Supplemental Table 3³&85(´PRGHORISURJQRVWLFIDFWRUVIRUSHGLDWULFJHUPFHOOWXPRUV
including treatment with either cisplatin (PEb) or carboplatin (JEb) 
 
 
Factor Characteristic Estimated Log 
Odds  
(p value) 
Chemotherapy PEb - 
JEb -0.09 (0.73) 
Tumor Site Testicular - 
Ovarian 0.61 (0.25) 
Extra gonadal 0.15 (0.70) 
Tumor Site by 
Age Interaction 
Testicular and 
11+ Years 
- 
Ovarian and 11+ 
Years 
-0.90 (0.18) 
Extragonadal and 
11+ Years 
-1.48 (0.02) 
Extent of 
Disease 
  
Stage I-III - 
Stage IV -1.00 (0.001) 
Age at 
Enrollment 
10 years of age or 
less 
- 
11 years of age or 
older 
-0.16 (0.73) 
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Supplementary Table 4&KDUDFWHULVWLFVRI5&7RI&DUERSODWLQYV&LVSODWLQLQ0HQZLWK³*RRG5LVN´16-GCT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**Differences among the two treatment arms other than the choice of platinum agent are shown in bold. 
 
z 20% of the initial patients in this trial were treated with a dose of carboplatin <500 mg/m2  
z Time-interval was not reported. 
z Only the first 22 patients in the cis-platin arm were randomized. The last 17 pDWLHQWVZHUH³DVVLJQHG´FLVSODWLQEHFDXVHFDUERSODWLQZDVQR
longer available. 
 
AUC, area under the curve; B, bleomycin; C, carboplatin; CR, complete response; d, days; E, etoposide; EORTC, European Organization for 
Research and Treatment of Cancer; I, ifosfamide; IGCCCG, International Germ Cell Cancer Collaborative Group; MSKCC, Memorial Sloan-
Kettering Cancer Center; MRC, Medical Research Council; N/A, not available; NS, non-seminoma; P, cisplatin; S, seminoma; V, vinblastine.  
Study 
[Reference] 
Risk 
Criteria 
Histology Testes 
Site (%) 
No. of 
Patients 
Chemotherapy Regimen** Event-free 
survival 
Bajorin et al. 
[7] 
MSKCC NS+S 96 131 EC 
 
134 EP 
 
C 500 mg/ma and E 500 mg/m2 q28d x 4 
 
P 100 mg/m2 and E 500 mg/m2 q21d x 4 
74% at 3y 
 
87% at 3y* 
Tjulandin et 
al. 10] 
Indiana NS +S 95 23 EC 
 
39 EPc 
 
C 350 mg/m2 and E 500 mg/m2 q28d x 4 
 
P 100 mg/m2 and E 500 mg/m2 q21d x 4 
61%b 
 
79% 
Bokemeyer 
et al. [8] 
Indiana NS 100 25 CEB 
 
29 PEB 
C to achieve AUC 5 mg/mL/min, E 360 mg/m2, 
and B 90 mg q21d x 4c 
P 100 mg/m2, E 500 mg/m2 and B 90 mg q21d 
x 3  
63% at 2y 
 
74% at 2y* 
 
Horwich et 
al. [9] 
MRC / 
EORTC 
NS 100 298 
CEB 
 
300 
PEB 
C to achieve AUC 5 mg/mL/min, E 360 mg/m2 
and B 30 mg q21d x 4 
P 100 mg/m2, E 360 mg/m2 and B 30 mg q21d 
x 4 
77% at 1y 
 
91% at 1y 
